Summary of COVID-19 ibuzatrelvir studies
Studies
Meta Analysis
Hide extended summaries
RCT 240 outpatients showing significant viral load reduction with ibuzatrelvir (an oral SARS-CoV-2 Mpro inhibitor) compared to placebo. The study enrolled non-hospitalized adults aged 18-65 with symptomatic COVID-19 (≤5 days) and positive rapid antigen test, excluding those with obesity, smoking, chronic conditions, or immunocompromised status. Patients were randomized 1:1:2:2 to receive 100mg, 300mg, or 600mg ibuzatrelvir or placebo twice daily for 5 days. There were dose-dependent decreases in viral load at days 3 and 5 compared to placebo. The trial has limited generalizability due to strict exclusion criteria that eliminated many high-risk patients who would typically be candidates for antiviral therapy.
Nov 2024, Clinical Infectious Diseases, https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae529/7863440, https://c19p.org/mortezavi
1. Mortezavi et al., Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19
133 patient ibuzatrelvir early treatment RCT: 27% improved viral clearance (p=0.0001).RCT 240 outpatients showing significant viral load reduction with ibuzatrelvir (an oral SARS-CoV-2 Mpro inhibitor) compared to placebo. The study enrolled non-hospitalized adults aged 18-65 with symptomatic COVID-19 (≤5 days) and positive rapid antigen test, excluding those with obesity, smoking, chronic conditions, or immunocompromised status. Patients were randomized 1:1:2:2 to receive 100mg, 300mg, or 600mg ibuzatrelvir or placebo twice daily for 5 days. There were dose-dependent decreases in viral load at days 3 and 5 compared to placebo. The trial has limited generalizability due to strict exclusion criteria that eliminated many high-risk patients who would typically be candidates for antiviral therapy.
Nov 2024, Clinical Infectious Diseases, https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae529/7863440, https://c19p.org/mortezavi
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.